Chemiluminescence Immunoassay Market Size, Share, and Trends 2024 to 2034

Chemiluminescence Immunoassay Market Size and Growth

The global chemiluminescence immunoassay market size was valued at USD 7.22 billion in 2023 and is anticipated to reach around USD 15.15 billion by 2033, growing at a CAGR of 7.7% from 2024 to 2033.

Chemiluminescence Immunoassay Market Key Takeaways

• North America held market share of 51.14% in 2023.
• By application, the endocrine segment is expected to captured the biggest revenue share in 2023.
• By product, the consumables segment is expected to acquire the largest share of 70% in 2023.
• By end-users, the hospitals segment registered a maximum market share of 37% in 2023.

Chemiluminescence Immunoassay Market Size in the U.S. 2024 to 2033

The U.S. chemiluminescence immunoassay market size was estimated at USD 2.59 billion in 2023 and is predicted to be worth around USD 5.69 billion by 2033, at a CAGR of 8.2% from 2024 to 2033.

North America seized the substantial market stake globally in 2023 and is projected to mirror this trend during the assessment period. Significant influences backing to its governance are the existence of established healthcare infrastructure, high acceptance of cutting-edge chemiluminescence immunoassay solutions, and snowballing pervasiveness of chronic diseases among others. Additionally, augmented availability of novel CLIA systems in the U.S. on account of existence of crucial market participants like Beckman Coulter, Inc., Abbott Laboratories, Roche and DiaSorinis further likely to subsidize the growth of the market in the North America.

Asia Pacific is prospective to be an extremely profitable market for the chemiluminescence immunoassay analyzers market and it is anticipated to develop at a rapid growth rate throughout the estimate period. Huge population base and escalation in occurrence of infectious and chronic diseases augments requirement for diagnostic testing in the APAC. Besides, promising government initiative to progress healthcare infrastructure is expected to supplement the growth of the market.

Chemiluminescence Immunoassay Market Size in Europe 2023 to 2033

The Europe chemiluminescence immunoassay market size was calculated at USD 1.83 billion in 2023 and is projected to expand around USD 4.06 billion by 2033, poised to grow at a CAGR of 8.3% from 2024 to 2033.

Chemiluminescence Immunoassay Market Growth Factors

Diagnostic technology is budding rapidly, and over the last decade, considerable progress has been made in the identification of antibodies, progressively impending this sort of diagnostic to that of automated clinical chemistry laboratory. The number of tests integrating chemiluminescence immunoassay Analyzers practices is estimated to magnify on account of technological advancements in disease diagnosis, upsurge in demand for treatment monitoring and precautionary diagnosis. Subsequently, requirement for high throughput facilities are also increasing. Furthermore, large-scale laboratories are capturing benefit of service and quality constraints confronted by small and mid-volume laboratories to seize a bigger chunk of the market by means of CLIA methods.

Companion diagnostics comprise assays or tests proposed to support healthcare providers in taking treatment decisions for patients on the basis of finest response to therapy. The co-development of companion diagnostics along with therapeutic products has the latent to meaningfully modify the drug development process and commercialize drug candidates by getting safer drugs with improved therapeutic effectiveness cost-effectively and quickly. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics is expected to showcase a high growth potential.The Novel coronavirus epidemic is expected to influence market projections for the chemiluminescence immunoassays market. This is due to its possible application in eliminating the disease. Research is underway for the development of the peptide-based magnetic CLIA for serological diagnosis of the COVID-19 virus. This is a noteworthy development since this is the second diagnostic test afterwards real-time RT-PCR, which is the only existing laboratory test to check probable cases of contamination.

Chemiluminescence Immunoassay Market Scope

Application Insights

Numerous applications of chemiluminescence immunoassay market comprises of disorders, endocrine infectious diseases, oncology, cardiovascular disorders, hepatitis and retrovirus, allergy, drug discovery & development autoimmunity, and others. Endocrine gathered considerable market share in terms of revenue in 2023 and it is predicted to reflect this tendency throughout the estimate period. Foremost influences accountable for the governance of this application segment are incessant inventions in test offerings and extensive product offerings of chief and local manufacturers.

Product Insights

Among different product segments analyzed in this research study, consumables segment garnered substantial share more than 70% of the total market revenue generated in 2023. This segment is predicted to hold its domination over the prediction period. This growth can be credited to augmented requirement for consumables including stains and reagents in the area of endocrinology, therapeutic drug monitoring, and disease analysis. 

End-user Insights

In terms of several end-users, hospitals grasp majority of the market chunk and reported prime revenue share of more than 37% in 2023. This governance is credited to the cumulative need for chemiluminescence immunoassay solutions in hospitals and intensifying hospital visits on account of mounting occurrence of infectious diseases and cancer. Correspondingly, the growing hospitalization owed to outburst of novel coronavirus is anticipated to increase the requirement for chemiluminescence immunoassay solutions in the hospital segment. Snowballing amount of applications of automated CLIA analyzers in oncology, therapeutic drug monitoring, and companion diagnostics and emergence of integrated modules of automated CLIA analyzers are projected to fuel the growth of hospitals segment throughout the estimate period.

 Chemiluminescence Immunoassay Market Comapnies

• Hoffmann-La Roche AG
• Siemens Healthineers
• Abbott Laboratories
• DiaSorin S.p.A.
• Ortho Clinical Diagnostics
• Immunodiagnostic Systems
• Beckman Coulter Inc.
• Inova Diagnostics, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Maccura Biotechnology Co., Ltd
• Others

Segments Covered in the Report

By Product

• Consumables
• Instruments
• Automated
• Semi-automated
• Software & Services

By Application

• Cardiology
• Therapeutic Drug Monitoring
• Oncology
• Endocrinology
• Autoimmune Disease
• Infectious Disease
• Others

By End-use

• Clinical Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Others

By Regional Outlook

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Rest of EU
• Asia Pacific
  • China
  • India
  • Japan
  • Southeast Asia
  • Rest of APAC
• Middle East & Africa
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East and Africa
• Latin America
  • Argentina
  • Mexico
  • Brazil
  • Rest of Latin America